The impact of point‐of‐care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study
- 21 March 2022
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 29 (5) , 375-384
Abstract
Point‐of‐care (POC) diagnostics overcome barriers to conventional hepatitis C (HCV) testing in people who inject drugs. This study assessed impact on hepatitis C treatment uptake of POC HCV testing in needle and syringe exchange programs (NSPs). Rapid EC was a single‐arm interventional pilot study of HCV POC testing conducted in three inner‐city community clinics with NSPs. Twelve months after the POC testing, a retrospective medical record and Pharmaceutical Benefits Scheme audit was performed to determine the number of HCV RNA‐positive participants who were prescribed HCV treatment. 70 HCV RNA‐positive Rapid EC study participants were included. 44 (63%) were prescribed DAAs; 26 (59%) completed treatment and 15 (34%) had SVR testing, all of whom were cured. Age ≥ 40 years (aOR 3.45, 95% CI 1.10–11.05, p = .03) and secondary school education (aOR 5.8, 95% CI 1.54–21.80, p = .009) had higher likelihood of being prescribed DAAs, whereas homelessness was inversely associated with prescription of DAAs (aOR 0.30, 95% CI 0.09–1.04, p = .057). Median time to receive a DAA script from date of diagnosis was seven days (IQR 0 to 14 days), and time to filling the DAA prescription was 2 days (IQR 0–12 days). In conclusion, provision of POC testing through NSPs was effective for linking new clients to HCV treatment and reduced the time to treatment. Further studies are needed to define the most cost‐effective use of POC testing in models of care for people who inject drugs to increase HCV treatment uptake.Keywords
Funding Information
- Shepherd Foundation
- Gastroenterological Society of Australia
This publication has 22 references indexed in Scilit:
- Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in AustraliaInternational Journal of Drug Policy, 2018
- Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling studyJournal of Viral Hepatitis, 2018
- Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030Journal of Gastroenterology and Hepatology, 2018
- Understanding hepatitis C intervention success—Qualitative findings from the HepCATT studyJournal of Viral Hepatitis, 2018
- Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascadeInternational Journal of Drug Policy, 2017
- Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort studyThe Lancet Gastroenterology & Hepatology, 2017
- Cost‐effectiveness of treating chronic hepatitis C virus with direct‐acting antivirals in people who inject drugs in AustraliaJournal of Gastroenterology and Hepatology, 2016
- Australian recommendations for the management of hepatitis C virus infection: a consensus statementMedical Journal of Australia, 2016
- Novel population‐based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is neededHepatology, 2015
- Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS studyJournal of Viral Hepatitis, 2013